38 results about "Retinal neovascularization" patented technology

The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure, wherein the first therapeutic agent provides rapid improvement in the condition of the subject's eye and the second therapeutic agent is administered as a sustained release formulation of the second therapeutic agent. For example, the first and second therapeutic agents are administered by intravitreal injection. The first therapeutic agent may be dissolved in a liquid medium located in the syringe and the sustained formulation of the second therapeutic agent may comprise an ocular implant or plurality of particles located in the needle. The therapeutic agents may be selected from the group consisting of angiogenesis inhibitors and complement inhibitors.

Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

Methods and compositions are provided for the treatment of diseases such as exudative macular degeneration, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, retinal neovascularization, iris neovascularization, corneal neovascularization, ocular tumors, and other disorders of the eye, cancer, and inflammatory disorders. The method involves administering a conjugate, referred to as fVIIPD, containing a photosensitizer and a targeting molecule such as factor VII (“fVII”), fVIIa, or modified fVII, which binds with high affinity and specificity to tissue factor (TF). TF is more highly expressed, abnormally expressed or specifically expressed on endothelial cells lining the luminal surface of pathological neovasculature, than on normal vasculature, thus providing a specific and accessible therapeutic target. Following administration of fVIIPD, the compound specifically binds to the pathological neovasculature of the eye by interaction of the targeting molecule with TF expressed by endothelial cells within abnormal blood vessels. The photosensitizer may then be activated with a non-thermal laser light for selective destruction of abnormal vasculature.

The present invention relates to the use of a compound of Formula (IIV) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and / or prophylaxis of any of the diseases selected from the group consisting of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy.

The invention discloses a construction method and application of a retinal neovascularization disease model, and relates to the field of biotechnology. The construction method knocks out the Tmem30a gene sequence in the genome of the target animal vascular endothelial cells, so that the target animal exhibits the typical retinal neovascularization disease characteristics. The target animal can beused as a model of retinal neovascularization disease, which can help to clarify the pathogenesis and mechanism of retinal neovascularization disease, and provide a new target for the treatment or prevention of retinal neovascularization disease.

The invention provides an ophthalmic preparation as well as a preparation method and application thereof. The invention discloses an ophthalmic preparation for inhibiting ocular retinal leakage and / or reducing the number of retinal neovascularization. The ophthalmic preparation comprises vitamin A or pharmaceutically acceptable salt thereof and transthyretin, the transthyretin is a protein composed of amino acids as shown in SEQ ID NO: 1. The content of the transthyretin is 5 to 30 [mu] mol / L; the content of the vitamin A or the pharmaceutically acceptable salt thereof is 2-10 [mu] mol / L. The invention also provides a preparation method and application of the ophthalmic preparation. The transthyretin and the compound in the ophthalmic preparation can cooperate with each other, so that the treatment effect on eye diseases related to eye angiogenesis and / or eye retina leakage can be remarkably improved when the ophthalmic preparation is used for treating the eye diseases.

The invention discloses a method and application for constructing a retinal neovascularization disease model, and relates to the field of biotechnology. Specifically, this method knocks out the Ctnna1 gene in the vascular endothelial cells of the target animal through gene editing technology, or silences the expression of the Ctnna1 gene in the vascular endothelial cells of the target animal through RNAi technology, so that the target animal shows typical retinal neogenesis The characteristics of vascular diseases, the disease model can be used as a disease model of new retinal blood vessels, and it provides convenience for the study of the pathogenesis and mechanism of retinal neovascular diseases, and also provides a new target for the treatment or prevention of the disease .